Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RBX 7455

Drug Profile

RBX 7455

Alternative Names: Microbiota Restoration Therapy - Rebiotix; RBX-7455

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rebiotix
  • Developer Mayo Clinic; Rebiotix
  • Class Antibacterials; Antineoplastics; Bacteria
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Clostridium difficile infections
  • Phase II Hepatic encephalopathy
  • No development reported Breast cancer

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in Breast-cancer in USA (PO, Capsule)
  • 13 Oct 2023 Rebiotix terminates a phase II trial for Hepatic Encephalopathy in the US (PO, Capsules), since the company was unable to recruit participants (NCT04155099)
  • 04 Oct 2023 Mayo Clinic terminates phase I trial in Breast cancer in the US due to poor accrual (NCT04139993)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top